Jan H M Schellens Selected Research

Nausea

1/2021	A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
1/2020	Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
1/2020	Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
1/2019	A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
12/2016	Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
2/2015	Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.
5/2013	The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
11/2011	The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
10/2011	Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial.
9/2011	Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jan H M Schellens Research Topics

Disease

186	Neoplasms (Cancer) 05/2024 - 04/2002
70	Breast Neoplasms (Breast Cancer) 01/2020 - 04/2002
20	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 11/2002
19	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 09/2004
15	Neutropenia 01/2020 - 05/2002
12	Nausea 01/2021 - 09/2007
11	Melanoma (Melanoma, Malignant) 05/2024 - 09/2002
11	Carcinoma (Carcinomatosis) 01/2023 - 10/2003
10	Fatigue 01/2021 - 09/2011
9	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 02/2007
8	Disease Progression 01/2022 - 11/2007
8	Vomiting 01/2021 - 09/2007
8	Ovarian Neoplasms (Ovarian Cancer) 01/2018 - 01/2002
8	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 05/2007
7	Dihydropyrimidine Dehydrogenase Deficiency 01/2024 - 01/2012
7	Diarrhea 01/2020 - 09/2011
6	Exanthema (Rash) 01/2021 - 06/2011
6	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2006
6	Thrombocytopenia (Thrombopenia) 01/2020 - 06/2005
5	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 03/2005
5	Hypertension (High Blood Pressure) 01/2017 - 12/2009
4	Adenocarcinoma 01/2023 - 03/2010
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 09/2004
4	Stomach Neoplasms (Stomach Cancer) 02/2016 - 03/2010
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2013 - 08/2002
3	Glioma (Gliomas) 01/2023 - 04/2005
3	Ototoxicity 01/2021 - 02/2006
3	Fever (Fevers) 01/2021 - 07/2009
3	Hyperphosphatemia 01/2020 - 01/2017
3	Circulating Neoplastic Cells 01/2020 - 12/2011

Drug/Important Bio-Agent (IBA)

40	Proteins (Proteins, Gene)FDA Link 09/2017 - 04/2002
23	Biomarkers (Surrogate Marker)IBA 01/2018 - 03/2005
20	Capecitabine (Xeloda)FDA Link 11/2023 - 03/2004
18	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 08/2002
18	Gemcitabine FDA Link 01/2020 - 11/2002
18	Docetaxel (Taxotere)FDA Link 01/2020 - 11/2004
17	Tyrosine Kinase InhibitorsIBA 12/2018 - 04/2005
16	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 08/2016 - 10/2004
15	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 11/2006
13	PlatinumIBA 01/2021 - 05/2002
11	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2024 - 12/2011
11	Monoclonal AntibodiesIBA 01/2023 - 08/2009
11	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 04/2004
10	olaparibIBA 01/2021 - 07/2009
10	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 05/2004
10	Adenosine Triphosphate (ATP)IBA 07/2017 - 10/2002
9	Fluorouracil (Carac)FDA LinkGeneric 05/2020 - 01/2006
9	Trastuzumab (Herceptin)FDA Link 01/2018 - 08/2009
8	pazopanib FDA Link 06/2018 - 11/2011
8	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 08/2008
8	Topotecan (Hycamtin)FDA LinkGeneric 07/2009 - 01/2002
7	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 09/2002
7	Cetuximab (Erbitux)FDA Link 10/2019 - 05/2011
7	Peptides (Polypeptides)IBA 12/2011 - 01/2010
7	N- (3- chloro- 7- indolyl)- 1,4- benzenedisulphonamide (E7070)IBA 10/2011 - 09/2002
6	trametinibIBA 01/2023 - 01/2018
6	dabrafenibIBA 01/2023 - 03/2015
6	Phosphotransferases (Kinase)IBA 12/2018 - 08/2010
6	ErbB Receptors (EGF Receptor)IBA 01/2018 - 08/2008
6	Tamoxifen FDA LinkGeneric 01/2017 - 01/2013
6	Ritonavir (Norvir)FDA Link 03/2016 - 04/2004
6	Blood Proteins (Serum Proteins)IBA 07/2010 - 03/2006
6	TrabectedinIBA 01/2009 - 04/2002
5	CamptothecinIBA 01/2022 - 12/2004
5	Type I DNA Topoisomerases (Topoisomerase I)IBA 03/2020 - 01/2002
5	ElacridarIBA 01/2018 - 10/2004
5	AnthracyclinesIBA 01/2018 - 04/2002
5	Cytochrome P-450 CYP3AIBA 02/2016 - 01/2006
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2016 - 08/2007
5	EnzymesIBA 02/2015 - 01/2006
5	Irinotecan (Camptosar)FDA LinkGeneric 04/2013 - 09/2004
5	DNA AdductsIBA 07/2009 - 09/2002
4	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 01/2024 - 01/2006
4	TabletsIBA 01/2021 - 06/2013
4	Panitumumab (Vectibix)FDA Link 01/2020 - 12/2015
4	Estrogen ReceptorsIBA 01/2018 - 12/2013
4	human ERBB2 proteinIBA 01/2018 - 01/2016
4	Bevacizumab (Avastin)FDA Link 02/2016 - 05/2011
4	lenvatinibIBA 02/2015 - 08/2010
4	Imatinib Mesylate (Gleevec)FDA Link 06/2014 - 04/2005
4	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2014 - 10/2005
4	Methotrexate (Mexate)FDA LinkGeneric 02/2012 - 08/2004
3	UracilIBA 01/2022 - 07/2016
3	Messenger RNA (mRNA)IBA 10/2021 - 04/2002
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2021 - 08/2012
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 05/2010
3	PolymersIBA 01/2021 - 05/2004
3	ProdrugsIBA 05/2020 - 11/2008
3	LigandsIBA 01/2020 - 01/2015
3	Lapatinib (GW572016)FDA Link 01/2020 - 08/2007
3	Epithelial Cell Adhesion MoleculeIBA 01/2020 - 01/2016
3	Capsules (Microcapsules)IBA 01/2020 - 01/2018

Therapy/Procedure

55	Therapeutics 12/2023 - 04/2002
22	Drug Therapy (Chemotherapy) 11/2023 - 04/2002
8	Radiotherapy 01/2021 - 08/2006
7	Drug Tapering 01/2019 - 05/2007
6	Oral Administration 01/2020 - 06/2004
4	Aftercare (After-Treatment) 03/2016 - 04/2004
3	Castration 01/2022 - 01/2019
3	Intravenous Administration 01/2020 - 05/2007